Section 2.
Each ml contains 408.2 mg Iopamidol.
For excipients, see 6.1.
Section 4.2
Route of administration
Intra-thecal
Intra-cisternal
Method of administration
No other drugs should be mixed with the contrast medium.
Lumbar myelography
A slow sub-arachnoid injection is made through a fine lumbar puncture needle into one of the lower lumbar interspinous spaces (L3-L4 or L4-L5) Optimum contrast appears immediately after injections and films should be obtained promptly.
Thoraco-cervical myelography
Following a slow sub-arachnoid injection the patient should be turned on his side and tilted 10°-20° head down under fluoroscopic control. In this manner it is possible to control movement of the contrast medium column into the dorsal region.
If the cervical region is to be examined, the contrast medium should be run into the cervical region first, before the examination of the dorsal areas where it is progressively diluted.
Niopam may also be injected sub-occipitally or by lateral cervical puncture technique. Care should be taken to ensure that the contrast medium does not move intra-cranially.
Following intra-thecal use, the patient should rest with the head and chest elevated for one hour and be kept well hydrated. Thereafter, he/she may ambulate carefully but bending down be avoided. If remaining in bed, the head and chest should be kept elevated for 6 hours. Patients suspected of having a low seizure threshold should be observed during this period.
Computer tomography enhancement
Contrast enhancement for brain scans can be achieved between one and three minutes after i.v. injection. Niopam 200 is also used for total body scanning examinations after i.v. administration as a bolus, as a drip infusion or by a combination of the two methods.
Section 4.3
Because of overdosage considerations, immediate repeat myelography in the event of technical failure is contraindicated.
Section 4.4
X-ray examination of women should if possible be conducted during the pre-ovulation phase of the menstrual cycle and should be avoided during pregnancy. – Removed from this section
Waldenströms macroglobulinemia, multiple myeloma - inserted
Niopam should be administered with caution in elderly patients and patients with increased intracranial pressure or suspicion of intracranial tumour, abscess or haematoma, and in those with a history of epilepsy, severe cardiovascular disease, renal impairment, chronic alcoholism or multiple sclerosis. Patients with these conditions have an increased risk of neurological complications.
General anaesthesia may be indicated in selected patients. However, a higher incidence of adverse reactions has been reported in these patients, probably due to the hypotensive effect of the anaesthetic.
Contrast media may promote sickling in individuals who are homozygous for sickle cell disease when injected intravenously.
Patients with phaeochromocytoma may develop severe hypertensive crisis following intravascular Iopamidol. Pre-medication with a-receptor blockers is recommended.
The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.
Patients with congestive heart failure should be observed for several hours following the procedure to detect delayed haemodynamic disturbances, which may be associated with a transitory increase in the circulating osmotic load. All other patients should be observed for at least one hour after the procedure, as most of the adverse events occur in this period. The patient should also be informed that allergic reactions may develop up to several days after the procedure; in such case, a physician should be consulted immediately.
In neonates, and particularly in premature neonates, it is recommended that tests of thyroid function (typically TSH and T4), should be checked 7-10 days and 1 month after the administration of iodinated contrast media because of the risk of hypothyroidism due to iodine overload. In patients scheduled for thyroid examination with a radioactive iodine tracer, one must take into consideration that iodine uptake in the thyroid gland will be reduced for several days (up to two weeks) after dosing with an iodinized contrast medium that is eliminated through the kidneys.
Local tissue irritation can occur as an event of perivascular infiltration.
Neuroleptics must be absolutely avoided because they lower the seizure threshold. The same applies to analgesics, anti-emetics, antihistamines and sedatives of the phenothiazine group. Whenever possible, treatment with such drugs should be discontinued at least 48 hours before administration of the contrast medium and not be resumed less than 12 hours after completion of the procedure.
Serious neurological events have been observed following direct injection of contrast media into cerebral arteries or vessels supplying the spinal cord or in angiocardiography due to inadvertent filling of the carotids.
Section 4.5
Thyroid function tests: As a consequence they will not accurately reflect thyroid function for up to 16 days following administration of iodinated contrast media. Thyroid function tests not depending on iodine estimations, e.g. T3 resin uptake and total or free thyroxine (T4) assays are not affected.
No other specific interference with physiological functions have been noted.
The administration of an X-ray contrast medium in diabetic patients with nephropathy who are taking biguanides may precipitate lactic acidosis.
Arterial thrombosis has been reported when Iopamidol was given following papaverine. The administration of vasopressors strongly potentiates the neurological effect of the intra-arterial contrast media.
Contrast media may interfere with laboratory tests for bilirubin, proteins or inorganic substances (eg iron, copper, calcium, phosphate). These substances should not be assayed during the same day following the administration of contrast media.
Section 4.6
Niopam is poorly excreted in human milk. From animal experience, Niopam is non toxic in animals after oral administration. Although, no serious adverse reactions have been reported in nursing infants, Niopam should be administered to lactating women only if considered essential by the physician.
Section 4.7
There is no known effect on the ability to drive and operate machines. However, because of the risk of early reactions, driving or operating machinery is not advisable for one hour following the last injection.
Section 4.8
The use of iodinated compounds may cause untoward side effects and manifestations of anaphylaxis. The symptoms include nausea, vomiting, diffuse erythema, feeling hot, headache, rhinitis or laryngeal oedema, fever, sweating, asthenia, dizziness, pallor, dyspnoea, moderate hypotension. Skin reactions may occur in the form of various types of rash or diffuse blisters. More severe reactions involving the cardiovascular system such as vasodilatation with pronounced hypotension, tachycardia, dyspnoea, agitation, cyanosis, loss of consciousness and cardiac arrest, may require emergency treatment.
The occurrence of delayed intolerance reactions, most commonly pruritus and urticaria, has been reported up to several days post administration.
During intra-cardiac and/or coronary arteriography, ventricular arrhythmias may infrequently occur.
Also cases of myocardial ischemia or infarction and/or cardiac failure/cardiac arrest have been reported rarely.
Other undesirable effects are:
- renal impairment,
- thrombocytopaenia,
- asthma/bronchospasm, and
- pulmonary oedema.
Hyperthyroidism may recur in patients previously treated for Graves' disease.
After cerebral angiography, confusion; stupor; coma, paresis, cortical blindness (usually transient), and convulsions may occur.
Rarely, Steven-Johnson syndrome has been reported.
Local pain and swelling at the injection site may occur.
The possibility of an infective meningitis should be considered. Dizziness, pain in limbs, back , or neck pain may also occur.
Section 4.9
Treatment of overdosage is directed toward the support of all vital functions and the elimination of the contrast medium while maintaining the patient well hydrated.
If needed, haemodialysis can be used to eliminate Iopamidol from the body.
Section 5
Pharmacotherapeutic group; ATC code: V08A B04
Section 6.6
Exceptionally, the event of crystallisation of Niopam could occur. It has been shown that such a phenomenon is caused by a damaged or defective container and therefore the product should not be used in this case. The bottle, once opened, must be used immediately.
Any residue of contrast medium must be discarded.
Niopam, as other iodinated contrast media, can react with metallic surfaces containing copper (e.g. brass), therefore the use of equipment, in which the product comes into direct contact with such surfaces, should be avoided.
Section 9.
22nd March 1982 / 9th January 2002
Section 10.
29th July 2005
|
